Compare Crispr Therapeutics AG (CRSP) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs KB Financial Group, Inc. — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.88B), while KB Financial Group, Inc. trades at $121.96 (market cap $42.62B). The key difference: KB Financial Group, Inc. is far larger — about 8.7× Crispr Therapeutics AG's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and KB Financial Group, Inc. for 33 Days on average.
| CRSP | KB | |
|---|---|---|
Market Cap | $4.88B | $42.62B |
Volume | 2,861,747 | 164,291 |
Sector | Health | Financials |
52-Week High | $74.92 | $132.88 |
52-Week Low | $44.34 | $77.50 |
Typical Hold Time | 77 Days | 33 Days |
Enterprise Value | $3.30B | $215.53T |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
KB Financial Group (KB) trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and improving profitability metrics. Technical indicators suggest a neutral near-term outlook, while analyst sentiment leans cautious with a 66.7% hold rating. Recent news highlights institutional interest and positive momentum coverage from financial media.
The outlook for KB appears balanced with attractive valuation metrics including a P/E of 9.68 and P/B of 0.94 suggesting potential undervaluation. However, the mixed analyst consensus and elevated EV/EBITDA of 21.71 warrant caution. Key risks include exposure to South Korean economic conditions and banking sector volatility, while opportunities lie in continued earnings growth and dividend potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
